We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Boundless Bio Inc | NASDAQ:BOLD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.30 | 3.31% | 9.35 | 8.82 | 17.85 | 9.42 | 8.53 | 9.06 | 108,102 | 05:00:10 |
From May 2019 to May 2024
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October:
Chardan 3rd Annual Genetic Medicines Conference Fireside Chat: Monday, October 7, 2019, at 10:30am ET New York, New York
Jefferies Gene Therapy/Editing Summit Fireside Chat: Tuesday, October 8, 2019, at 9:10am ET Panel: “Manufacturing, Dose, and Durability in Gene Therapy,” Tuesday, October 8, 2019, at 10:20am ET New York, New York
To access live webcasts of the fireside chats, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the Manufacturing, Dose, and Durability in Gene Therapy panel at the Jefferies Gene Therapy/Editing Summit.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients.
For more information regarding Audentes, please visit www.audentestx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191001005060/en/
Investor Contact: Andrew Chang 415.818.1033 achang@audentestx.com
Media Contact: Sarah Spencer 415.957.2020 sspencer@audentestx.com
1 Year Boundless Bio Chart |
1 Month Boundless Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
